Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International collaborative protocol for pediatric acute lymphoblastic leukemia
DRKS00015289Phase 3Active, not recruiting
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Aug 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, randomised trial of bortezomib and blinatumomab in acute lymphoblastic leukemia (ALL) (12 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Started Aug 2018; status: active, not recruiting.
02
Drugs
bortezomibblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on DRKS00015289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00015289.